Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
How many aimovig injections are needed per month?Does lipitor's list of side effects include dizziness?How many advil tablets do you take for sleep?How do i prime the genotropin pen?How does lipitor alcohol interaction cause side effects?
See the DrugPatentWatch profile for simponi
Who Should Not Take Simponi? Simponi is a TNF inhibitor used to treat plaque psoriasis, psoriatic arthritis, ulcerative colitis, and rheumatoid arthritis [1]. However, there are certain individuals who should not take Simponi due to potential risks. Severe Hypersensitivity Reactions Simponi is contraindicated in patients with a history of severe hypersensitivity reactions to golimumab or any component of the product. These reactions may include anaphylaxis, angioedema, bronchospasm, and urticaria [2]. Active Infections Simponi should not be started in patients with active infections, such as sepsis, osteomyelitis, or tuberculosis. It may worsen or reactivate these infections [3]. Malignancies The use of Tumor Necrosis Factor (TNF) blockers like Simponi may increase the risk of lymphoma, skin cancer, and other malignancies. Patients with a history of malignancy may be at higher risk [4]. Weakened Immune System Simponi should not be used in patients with weakened immune systems, such as those with HIV/AIDS, due to the increased risk of infections and opportunistic infections [5]. Latent Tuberculosis Simponi may reactivate latent tuberculosis. Patients with a history of TB or those at risk of exposure should be screened and treated before starting the medication [6]. Pregnancy and Breastfeeding Simponi is a category B medication, indicating potential risks to the fetus. Women of childbearing potential should use effective contraception while taking Simponi and for 5 months after treatment. Other Contraindications Simponi is contraindicated in patients with a history of multiple sclerosis, Crohn's disease involving the upper part of the digestive tract, and in those taking certain medications, such as live vaccines and certain anti-TNF biologics. Monitoring and Warning Before starting Simponi, patients should be monitored for signs of infection, malignancy, and TB reactivation. It is essential to discuss potential risks and benefits with a healthcare professional. References [1] Simponi (golimumab) label. (n.d.). Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125330s034lbl.pdf [2] Drugs.com. (n.d.). Simponi. Retrieved from https://www.drugs.com/pro/simponi.html [3] Simponi (golimumab) package insert. (n.d.). Retrieved from https://www.drugs.com/pro/simponi.html [4] Mayo Clinic. (n.d.). Tumor necrosis factor inhibitors. Retrieved from https://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/expert-answers/tumor-necrosis-factor-inhibitors/faq-20058492 [5] AIDSinfo. (n.d.). Golimumab. Retrieved from https://aidsinfo.nih.gov/drugs/1157/golimumab [6] TB Alliance. (n.d.). TB Reactivation. Retrieved from https://www.tballiance.org/tuberculosis-101/tb-reactivation/
Other Questions About Simponi :